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Abstract
Background: Serous ovarian cancer (SeOvCa) is an aggressive disease with differential and often inadequate therapeutic
outcome after standard treatment. The Cancer Genome Atlas (TCGA) has provided rich molecular and genetic profiles from
hundreds of primary surgical samples. These profiles confirm mutations of TP53 in ,100% of patients and an extraordinarily
complex profile of DNA copy number changes with considerable patient-to-patient diversity. This raises the joint challenge
of exploiting all new available datasets and reducing their confounding complexity for the purpose of predicting clinical
outcomes and identifying disease relevant pathway alterations. We therefore set out to use multi-data type genomic
profiles (mRNA, DNA methylation, DNA copy-number alteration and microRNA) available from TCGA to identify prognostic
signatures for the prediction of progression-free survival (PFS) and overall survival (OS).
Methodology/Principal Findings: We implemented a multivariate Cox Lasso model and median time-to-event prediction
algorithm and applied it to two datasets integrated from the four genomic data types. We (1) selected features through
cross-validation; (2) generated a prognostic index for patient risk stratification; and (3) directly predicted continuous clinical
outcome measures, that is, the time to recurrence and survival time. We used Kaplan-Meier p-values, hazard ratios (HR), and
concordance probability estimates (CPE) to assess prediction performance, comparing separate and integrated datasets.
Data integration resulted in the best PFS signature (withheld data: p-value=0.008; HR=2.83; CPE=0.72).
Conclusions/Significance: We provide a prediction tool that inputs genomic profiles of primary surgical samples and
generates patient-specific predictions for the time to recurrence and survival, along with outcome risk predictions. Using
integrated genomic profiles resulted in information gain for prediction of outcomes. Pathway analysis provided potential
insights into functional changes affecting disease progression. The prognostic signatures, if prospectively validated, may be
useful for interpreting therapeutic outcomes for clinical trials that aim to improve the therapy for SeOvCa patients.
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Introduction
Ovarian cancer is considered a ‘‘silent’’ disease, as 70% of
patients are diagnosed at an advanced stage with high grade serous
ovarian cancer (SeOvCa) [1]. The standard treatment requires
cytoreduction surgery followed by administration of platinum and
taxane-based chemotherapy. In a large number of patients with
advanced stage papillary SeOvCa (stages III/IV) that initially
respond to primary treatment with surgery and chemotherapy,
cancer recurs with a drug-resistant phenotype (25% cases within 6
months) and overall 5-year survival is 31% [1]. Consequently,
there is an urgent need for diagnostic molecular features or
biomarkers that can be associated with survival and disease
recurrence in SeOvCa.
Recently, mRNA expression signatures that predict platinum-
resistance [2], progression- free survival [3] or overall survival
[2,4,5] have been developed. Although these studies provided
valuable first clues to molecular changes in SeOvCa that might be
exploited in new treatment strategies, most of them suffered from
limited sample size, and the number of overlapping genes in the
identified profiles was minimal. It is well known that statistically
derived signatures are not necessarily unique, possibly because of
individual variation, heterogeneity [6] or collinearity [7]. Howev-
er, given the diversity and extent of copy number alterations in
SeOvCa genome, having a large sample size is a prerequisite for
accurately identifying alterations that could be most associated
with tumor recurrence and patient overall survival. A meta-
analysis using nine published gene sets [8] found, among others,
oxidative stress response mediated by NRF2, TP53 signaling and
TGFb signaling to be associated with platinum based therapy
resistance.
Since clinical decisions are usually binary, methods like support
vector machines [9,10] and univariate Cox regression are typically
utilized to stratify patients into binary categories such as bad-
prognosis and good-prognosis (or low- and high-risk). However, the
availability of clinical time data provides an opportunity to directly
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signature that can be reduced to binary decisions with no loss of
information. Clinical time-to-event prediction is possible but is a
relatively unexplored field and a challenging task.
The Cancer Genome Atlas (TCGA) project was established to
profile large tumor sets at both the DNA and RNA level to create
an integrated atlas of the aberrations present in tumor cells.
Ovarian Cancer is the second tumor type analyzed by TCGA, and
the study focused on newly diagnosed untreated invasive high-
grade SeOvCa samples.
Using TCGA data, the aims of our study were to (1) develop
molecular signatures of individual data types (mRNA expression,
microRNA expression, DNA methylation and copy-number
alteration data from primary surgical samples) associated with
platinum-free interval, progression-free survival and overall
survival in advanced-stage SeOvCa; (2) integrate four different
data types and compare the performance of genomic integration
with the individual data types; (3) test the predictive power of our
signatures in withheld data, and, wherever possible, in other fully
independent and publicly available datasets of high-grade
SeOvCa; and (4) derive the network of interactions and associated
pathways and transcription factors.
To achieve these goals, we utilized the wealth of information
available from TCGA and implemented an L1-regularized Cox
proportional hazards model to do feature selection using the Cox
model with an L1 penalty as proposed by Park and Hastie [11].
Previously published mRNA expression datasets were used to test
our gene signatures created from TCGA mRNA expression data.
Further we investigated the network of interactions and associated
pathways resulting from our signatures and identified pathways
and processes that could possibly explain the biological behavior of
SeOvCa.
Results and Discussion
Clinical Characteristics of the TCGA Data
Outcome measures of interest for our analysis were overall
survival (OS), progression-free survival (PFS) and platinum-free
interval (PFI) (Table 1). OS was defined as the time between the
initial surgical resection to the date of last follow-up or death. PFS
was defined as the interval from the date of initial surgical
resection to the date of progression, date of recurrence, or date of
last known contact, if the patient was alive and has not recurred.
PFI was defined as the interval from the date of last primary
platinum treatment to the date of progression, date of recurrence,
or date of last known contact if the patient is alive and had not
recurred. Tumor recurrence was defined using criteria customary
to the contributing institution. Platinum status was defined as
resistant if the PFI was less than six months and the tumor had
progressed or recurred. Platinum status was defined as sensitive if
the platinum free interval was six months or greater, there was no
evidence of progression or recurrence, and the follow-up interval
was at least six months from the date of last primary platinum
treatment [1].
PFS and PFI data were only available for a subset of patients
(Table 1) and were last updated on September 13, 2010. The PFI
and PFS outcome measures were directly correlated with each
other (Figure 1A), and PFS and OS outcome measures were not
(Figure 1B). Therefore, our approach was to identify different
signatures to predict PFS and OS, respectively. We chose to
predict PFS rather than PFI for two reasons: 1) there were ,100
more cases available with PFS information than PFI (potential for
improving the statistical performance of molecular signatures
identified), and 2) PFS is the outcome measure that is generally
reported in the literature.
Molecular Signature from Individual Data types
To achieve our first goal of deriving molecular signatures from
individual data types (mRNA expression, microRNA expression,
DNA methylation and copy-number alteration data) most
associated with tumor recurrence and survival, we implemented
a multivariate Cox Lasso model. This model is a path following
algorithm for L1-regularized Cox proportional hazards model [11]
and reports the markers of outcome through a cross-validation
procedure and maximization of concordance probability esti-
mates.
A potential issue in developing predictive signatures is over-
fitting to the training dataset, resulting in a signature that reflects
the characteristics of the training set but cannot accurately predict
outcome in the test set. Consequently, a fairly rigorous cross-
validation procedure of the regression model was followed and the
models were parameterized during the training procedure and
fixed before moving to the test data analysis. For creating the
training set, 316/395 cases with PFS data and 384/481 cases with
OS data were randomly chosen, and the rest were used as a blind
test set of the resulting molecular signatures. Three measures of
performance of the signatures for the test data were selected: p-
value (the measure of how well the signature stratifies patients into
broadly defined health-risk categories), Hazard ratios (HR, the
ratio of rate at which patients in two groups are experiencing
events), and concordance probability estimates (CPE, a measure of
how well our signatures predict the correct order of median time-to-
event). The cross-validation CPE (cv.CPE) and the CPE of the test
data (CPE.test) are provided for each data type. The total number
of features resulting from the four individual data types and the
respective integrated versions for the two outcome measures are
summarized in Table 2.
Copy-number Alteration Data. Given the extent of copy
number alterations (CNA) and the relatively low number of
significantly mutated genes observed in SeOvCa, it is considered a
copy-number driven disease. Consequently, we tried to identify
Table 1. Clinical characteristics of the TCGA data.
Cohort OS PFS/TTP PFI
Number of patients 481 395 287
Median Age 59.1 58.7 58.7
Serous 481 395 287
Platinum status
Sensitive 195 195 195
Resistant 92 92 92
Recurrent disease
No 113 113 40
Yes 282 282 247
Vital status
Alive 213 194 116
Dead 268 200 170
Median time, months 43.6 16.8 10.4
The total number of TCGA patients available (and associated clinical
characteristics) within each clinical outcome measure category are reported. All
outcome measures are depicted in the units of months.
doi:10.1371/journal.pone.0024709.t001
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measures.
Using our methodology, 167 copy-number features (genes) were
found to be most associated with PFS and 278 features most
associated with OS. All analysis details are provided in File S4.
The CPE.test for recurrence analysis was 0.67 and CPE.test for
survival analysis was 0.75 (Figures 4SA, 4SB in File S4). The
patient-risk stratification (tertile stratification using c-scores) for the
test set was not statistically significant for recurrence and survival
data (Table 2).
mRNA Expression, microRNA Expression and DNA
Methylation Data. The mRNA expression analysis for PFS
data identified 181 features that stratified TCGA test data with p-
value=0.05 (t-score) and 0.17 (c-score) and resulted in
CPE.test=0.77 (Figures 1SA, 1SB in File S1). For OS, 219
features were identified resulting in stratification p-value=0.09 (t-
score) and 0.70 (c-score) and CPE.test=0.80 (Figures 1SC, 1SD
in File S1). The DNA methylation analysis for PFS identified
140 features with p-value=0.03 (c-score, test data) and
CPE.test=0.72. For survival, DNA methylation identified 171
features with p-value=0.52 (c-score, test data) and CPE.test=0.74
(Figures 2SA, 2SB in File S2). The microRNA analysis for PFS
identified 81 features with p-value=0.09 (c-score, test data) and
CPE.test=0.63. For survival, microRNA analysis identified 87
features with p-value=0.09 (c-score, test data) and CPE.test=0.69
(Figures 3SA, 3SB in File S3).
Figure 1. Correlation of TCGA clinical outcome measures. (A) PFS and PFI are strongly correlated and do not need to be predicted separately.
(B) PFS and OS are not well correlated, so we derived separate predictive signatures for each (data only for un-censored patients).
doi:10.1371/journal.pone.0024709.g001
Table 2. Results from individual data types and the integrated versions.
Progression Free Survival (PFS)




p-val HR 95% CI
mRNA 181 0.77 0.17 0.05 1.97 (0.94, 4.11)
microRNA 81 0.63 0.09 NA 1.48 (0.75, 2.91)
DNA Methylation 140 0.72 0.03 NA 1.96 (1.05, 3.63)
Copy Number Alteration 167 0.67 0.61 NA 1.36 (0.71, 2.59)
Integrated data 156 0.72 0.008 0.004 2.83 (1.40, 5.74)
Overall Survival (OS)




p-val HR 95% CI
mRNA 219 0.80 0.70 0.09 1.26 (0.62, 2.55)
microRNA 87 0.69 0.09 NA 1.22 (0.63, 2.35)
DNA Methylation 171 0.74 0.52 NA 1.45 (0.77, 2.75)
Copy Number Alteration 278 0.75 0.18 NA 0.77 (0.39, 1.53)
Integrated data 182 0.73 0.59 0.81 1.10 (0.54, 2.22)
The number of features and four measures of performance are provided for the PFS (top) and OS (bottom) signatures. Hazard Ratio (HR) and 95% confidence interval
(CI) are reported for low-a n dhigh-risk groups based on Cox score (c-score) stratification.
doi:10.1371/journal.pone.0024709.t002
Predicting Outcome in Serous Ovarian Tumors
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e24709The details of the data processing, the methodology and results
from the three data types (mRNA expression, microRNA
expression and DNA methylation) are provided in Files S1, S2
and S3, respectively.
Based on the c-scores performance of the individual data types,
the DNA methylation signature is the most statistically significant,
the microRNA signature is borderline significant among PFS
signatures, and microRNA is borderline significant among OS
signatures (Table 2). The molecular signatures based on the
TCGA data were also tested in some external datasets (Table 3;
Figures 1SA, 1SB, 1SC, 1SD in File S1). This indicated the
robustness of the mRNA signatures and their broad applicability.
Molecular Signatures from Integrated Data
Causality is not necessarily established by a correlation between
a set of genes and clinical endpoints. Various mechanisms that
regulate gene expression include DNA methylation, histone
deacetylation, copy-number changes and targeting by micro-
RNAs. Therefore, an integration procedure that incorporates this
biologically useful knowledge and is computationally efficient was
highly desirable. We created a vector space integration method,
which is described in the Methods and Materials sections
(Figure 2). This methodology allowed us to directly compare the
performance of the integrated method with the performance of the
individual data types.
Progression-Free Survival. The result of the multivariate
Cox Lasso model using the integrated data was 156 features,
comprising 85 mRNA features, 47 DNA methylation features, 18
copy-number features, and 6 microRNA features that emerged as
being most associated with tumor recurrence. Tertile stratification
was performed on the training data. The resulting thresholds for
stratifying patients into low-, intermediate- and high-risk groups
resulted in a p-value of 8.0e-03 (c-score) and 4.0e-03 (t-score) for
the test data (Table 2, Figure 3). The concordance probability of
the test data (CPE.test) was 0.72 and HR between low- and high-
risk groups was 2.83. These results suggest an excellent predictive
power of the features for patient-risk stratification and median
time-to-event predictions for tumor recurrence.
Overall Survival. The multivariate Cox Lasso model using
integrated data resulted in 182 features that were most associated
with overall survival. This signature was comprised of 102 mRNA
features, 40 DNA methylation features, 30 copy-number features,
and 10 microRNA features. Tertile stratification was performed
on the training data. The resulting thresholds for stratifying
patients into low-, intermediate- and high-risk groups led to a p-value
of 0.59 (c-score) and 0.81 (t-score) for the test data. The CPE.test
was 0.73 (Figure 3). These results show inferior performance of the
integrated survival signature compared to the integrated PFS
signature. The median time-to-event prediction for the follow-up
times (PFS and OS) from the integrated datasets is provided in File
S5 (Figure 5SA).
Since the PFS signature identified from genomic integration had
the overall best performance (p=0.008; HR=2.83; CPE=0.72),
we limit the subsequent gene-set analysis and subsequent network
and pathway analysis to the PFS integrated signature.
Pathway Analysis of the PFS Signature Identified from
Genomic Integration
To identify common biological pathways and known interac-
tions of the 156 features in the integrated PFS signature, we
applied two different approaches: A) General over-representation
analysis to identify over-represented pathways and gene ontology
categories, and B) Network analysis to identify genes with evidence
for physical or functional interactions (connected in protein-
protein interaction or transcriptional networks).
A. Over-representation Analysis of the 156-feature Gene
Signature. Firstly, functional categories from IPA pathways
(Ingenuity, Inc.) [12] were used to identify pathways (more
precisely, gene sets grouped in pathways) over-represented in the
integrated PFS gene signature. Significant pathways (15 pathways
with p,0.05 and 23 pathways with p,0.1) containing more than
Table 3. Results for the mRNA prognostic signature applied
to external datasets.




p-val HR 95% CI
Tothill (OS) 219 0.80 0.047 0.014 2.06 (1.11, 3.30)
Dressman (OS) 219 0.78 0.008 0.033 1.33 (0.61, 2.88)
Bonome (OS) 219 0.75 0.049 0.180 1.77 (1.09, 2.88)
Tothill (PFS) 181 0.77 0.035 0.012 1.73 (1.10, 2.71)
Bonome (PFS) 181 0.77 0.870 0.880 1.06 (0.68, 1.66)
The number of features and four measures of performance are provided for the
PFS and OS mRNA signatures. Hazard Ratio (HR) and 95% confidence interval
(CI) are reported for low-a n dhigh-risk groups based on Cox scores (c-score)
stratification.
doi:10.1371/journal.pone.0024709.t003
Figure 2. Integration Procedure and CoxPath Methodology.
Integration combines multiple data types for the multivariate Cox
Proportional hazards model.
doi:10.1371/journal.pone.0024709.g002
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FccRIIB signaling in B lymphocytes, anti-proliferative role of
somatostatin receptor 2, G beta gamma signaling, oxidative
phosphorylation, breast cancer regulation by stathmin1,
pancreatic adenocarcinoma signaling, a-adrenergic signaling and
others (Figure 4). Interestingly, several genes are common to
several of the IPA gene sets, such as RRAS2, BTK, CD79A and
GNG12.
Secondly, IPA was also used to investigate the biological
functions and/or disease association of genes in the PFS signature
(31 categories with p,0.05 and genes $3 genes). These over-
represented categories included cell death & cell cycle; cancer;
DNA replication, recombination & repair; cell-to-cell signaling
and interaction; metabolic disease; drug & lipid metabolism;
inflammatory response; molecular transport, reproductive system
development & function; immune system trafficking, tumor
morphology; and cellular growth & proliferation and others
(Table S1).
In addition, to determine which Gene Ontology (GO) categories
are statistically overrepresented in the gene signature, we use the
Bingo software [13], which is available as a plugin in Cytoscape [14].
Eight GO categories (biological processes and molecular function)
were enriched among the 156 features. They were calmodulin-
dependent protein kinase activity and transferase activity, polysac-
charide metabolic process, protein amino acid ADP-ribosylation and
group transfer coenzyme metabolic process (corrected p-value,0.1;
Figure 5). We have not further investigated the details of these
functions potentially associated with tumor biology, but they
represent a guide to further analysis and, possibly, experiments.
B. Network Analysis of the 156-feature Gene Signature. In
order to investigate functional (sub)networks involving genes in the
PFS signature we applied Ingenuity Pathways Analysis [12] and the
network analysis algorithm Netbox [15].
Firstly, an IPA ‘‘Core Analysis’’ was used (graphical
representation) revealing four functional networks: cellular
growth and proliferation; hematological system development
Figure 3. Quality of outcome prediction for survival time (A, B) and discrete risk categories (C, D). (A) Prediction of time-to-event (PFS;
un-censored data); (B) prediction of time-to-event (OS; un-censored data); (C) statistically significant stratification into low-, intermediate- and high-risk
patients using the prediction method for TCGA test data based on c-score (Integrated PFS signature); and (D) stratification for the TCGA test data
based on t-score (Integrated PFS signature).
doi:10.1371/journal.pone.0024709.g003
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cell signaling and interaction, tissue development, cellular
movement (network-2); cell cycle, cell death and cancer
(network-3); and, cancer, gastrointestinal disease, genetic
disorder (network-4). Given the overlap between the networks
(TP53, FOXO3, NCF2, SIN3A, CCNB1), we merged the four
networks into a single network using the IPA ‘‘Merge
Networks’’ tool (Figure 6).
We next tried to identify the genes in this network that are most
discriminative between short and long-recurrence times. We
observed that BRCA2 (Breast Cancer 2 susceptibility protein;
mRNA) is expressed at higher levels in patients with shorter
recurrence time. Consistent with this observation, up-regulation of
BRCA2 (and BRCA1) has been observed in rapidly proliferating
and differentiating cells [16], and following exposure to cisplatin,
the DNA repair genes BRCA2 and FANCA have been observed
Figure 4. Canonical pathway analysis of 156 genes from the integrated PFS gene signature. IPA [12] identified 23 statistically significant
canonical pathways (p,0.1 and $3 genes).
doi:10.1371/journal.pone.0024709.g004
Figure 5. Overrepresented GO categories for genes in the integrated PFS signature. Six biological processes categories and two molecular
function categories were indentified by Bingo [13] containing (3,n,100) genes in the signature, a corrected p-value of ,0.1.
doi:10.1371/journal.pone.0024709.g005
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or in-directly, connected with TP53 (tumor protein p53). GPS2 (G
protein pathway suppressor 2) and BRCA2 have the largest
expression differences between patients with long and short
recurrence times. Interestingly, both of these genes are mutated
in SeOvCa, TP53 in 96.5% and BRCA2 in 9.2% of patients [1].
Secondly, Netbox (Figure 7) identified eight modules of
connected genes, ranging in size from three to 54 genes. Some
of the interactions identified by Netbox were common with those
identified by IPA (e.g., the module containing RALA, RRAS2,
RALBP1, ARHGEF2). To annotate the biological function of
these modules, we assessed over-representation of genes in each
module using IPA (Table S2). Module 1 was enriched in genes
involved in PI3K signaling in B lymphocytes, FccRIIB signaling in
B lymphocytes and p70S6K/mTOR signaling; module 2 was
enriched in genes involved in the protein ubiquitination pathway,
protein kinase A signaling, and DNA double-strand repair by
homologous recombination; and, module 3 was enriched among
others, for genes involved in phosphoslipase C signaling,
pancreatic adenocarcinoma signaling, and tight-junction signaling.
The genes below have been reported as implicated in cancer
and were identified by one or both of the pathway analysis tools.
PGRMC1 (Progesterone Receptor Membrane Component 1;
Xq24; mRNA) was down-regulated in patients with short
recurrence time. Interestingly, depleting PGRMC1 in ovarian
tumors makes these tumors more resistant to cisplatin treatment
(consistent with our observation) [18], and this gene is down-
regulated in breast cancer specimens compared to control tissues
[19]. CITED2 (Cbp/p300-interacting transactivator with
Glu/Asp-rich carboxy-terminal domain 2; 6q24.1; mRNA) up-
regulation is associated with shorter recurrence times. Knockdown
of CITED2 in cell lines results in increased sensitivity to cisplatin,
Figure 6. Network derived from the integrated PFS signature using IPA. The top four networks identified were merged using IPA analysis.
The features most discriminative between short and long-recurrence times are shown on larger scale. The nearest neighbor interactions of these
nodes are highlighted in different colors. Nodes are colored based on the mRNA expression profile of different genes (green: down-regulated in short
recurrence patients (PFS,6mo) compared to long recurrence (PFS.40mo), and red: up-regulated).
doi:10.1371/journal.pone.0024709.g006
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TFRC (Transferrin receptor; 3q29; mRNA) is up-regulated in
patients with shorter recurrence times, which is consistent with its
behavior in esophageal squamous cell carcinoma, where TFRC
up-regulation is associated with worse prognosis [21]. RALBP1
(ralA binding protein 1; 18p11.22; mRNA) acts as a transporter of
glutathione conjugates and chemotherapeutic drugs and serves as
a link between G-protein and tyrosine kinase signaling and drug
resistance [22]. In SeOvCa, RALA (ral-A; 7p14.1; mRNA) and
RALBP1 are down-regulated in patients with short recurrence
time compared to long-recurrence time. ALOX12 (arachidonate
12-lipoxygenase; 17p13.1; METH) acts as a methylation marker
(hypermethylation) in pancreatic cancer genome [23] and
hypermethylation of ALOX12 is predictive of overall survival
(poor prognosis) in patients with acute myeloid leukemia [24]. In
the TCGA SeOvCa data set, ALOX12 is hypermethylated in
patients with longer recurrence intervals. ARHGEF2 (rho/rac
guanine nucleotide exchange factor 2; 1q22; METH) is a member
of the Dbl family of Rho activators and it has Rho-specific GDP/
GTP exchange activity for RhoA [25]. Activated RhoA contrib-
utes to cancer progression by transducing various signals into
downstream signaling cascades, such as cytoskeleton reorganiza-
tion, cellular invasion, and cell proliferation [25]. Increased
ARHGEF2 expression contributes to the tumor progression
phenotype associated with p53 mutation [26]. ID4 (inhibitor of
DNA binding 4; 6p22.3; METH) belongs to the ID family of
transcription factors, and its methylation status acts as a prognostic
biomarker in some cancers [27]. In TCGA data, lower
methylation beta values and higher expression are associated with
shorter recurrence times. ID4 has been identified as a transcrip-
tional target of the protein complex mutant p53/E2F1/p300 in
breast cancer [28]. Some of these genes are candidates for targeted
experiments.
C. Potential Biomarkers and Therapeutic Targets for
Ovarian Cancer. Identifying biomarkers and therapeutic
targets for SeOvCa patients is a challenge given the complexity
and heterogeneity of genomic alterations in this cancer. In order to
suggest possible biomarkers and therapeutic targets, we ranked the
156 features in the PFS signature based on their individual power
(Table S3). Based on the probability distribution of each of
features, we stratified all SeOvCa patients into three categories:
low (bottom 15% values), intermediate, and high (top 15% values).
Out of the 12 most discriminant features in the integrated PFS
signature, ID4, CA2, and C1ORF114 are up-regulated in tumors
with short recurrence times, and RNF10, SLAMF7, HOXA4,
CD79A, RALA, ALOX12, PSRC1, CAMKK2, and CHIT1 are
down-regulated in tumors with short recurrence times (Figure 8).
In addition to ID4 and ALOX12, which are discussed above,
several of these genes are known to be implicated in cancer:
RNF10 (ring finger protein 10; 12q24.31) has been implicated
in cellular processes such as signal transduction, transcriptional
regulation, ubiquitination and apoptosis [29,30]. RNF10 expres-
Figure 7. Netbox modules identified using the integrated PFS signature. Different modules are spatially separated for visualization. The
genes present in our signature are shaped as octagons (mRNA features), diamonds (methylation features) and rectangles (copy number feature). The
linker nodes are represented as small circles. Nodes are colored based on the mRNA expression profile of different genes (green: down-regulated in
short recurrence patients (PFS,6mo) compared to long recurrence (PFS.40mo), and red: up-regulated).
doi:10.1371/journal.pone.0024709.g007
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global analysis with all microRNAs, we found that RNF10
expression was most strongly anti-correlated with miR-92A
(cc=20.14). RNF10 is a predicted target of miR-92a, (Targetscan
pct score=0.75). SLAMF7 (SLAM family member 7; 1q23.3)
down-regulation is associated with decreased phosphorylation of
ERK1/2, STAT3 and AKT, as well as altered phosphorylation of
multiple kinases, inducing signaling cascade in multiple myeloma
[31]. In TCGA data, SLAMF7 is down-regulated in patients with
faster recurrence and its expression is not clearly associated with
either CNA data or DNA methylation. TCGA data is suggestive of
possible targeting by miR-129-5p (cc=20.18; pct=0.33).
HOXA4 (homeobox A4; 7p15.2) is highly expressed in invasive
ovarian carcinomas compared to benign or borderline (non-
invasive) carcinoma [32]. In acute myeloid leukemia, low
expression of HOXA4 is a favorable outcome predictor [33]. In
TCGA data HOXA4 is methylated, and down-regulation is
associated with samples that show faster tumor recurrence.
CAMKK2 (calcium/calmodulin dependent protein kinase kinase
2; 12q24.31) is down-regulated in tumors with short-recurrence
time in TCGA data. Activating CAMKK2 in cervical cancer
inhibits human cancer cell growth in both LKB1-expressing and
LKB1-deficient cervical cancer cells [34]. This suggests that
CAMKK2 activation could indicate improved prognosis of
ovarian cancer patients. We suggest that these genes are
reasonable candidates for biomarker studies in SeOvCa.
Conclusions
We have made substantial progress in outcome prediction by
using data integration, rather than just a single genomic data type,
and by analyzing as many as 500 cases, more than the ,150 or so
available to earlier studies [3,5]. In part, the advance was made
possible by the Cancer Genome Atlas (TCGA) project, which
profiled more than 500 primary surgical samples from serous
ovarian carcinoma patients for copy number, microRNA and
mRNA expression, and DNA methylation, and provided clinical
information about disease recurrence and survival. We used this
dataset to perform both discrete stratification analysis and
continuous clinical time predictions.
Figure 8. Features from the integrated PFS signature ranked based on their stratification performance. Top ranked features
(categorized based on their values from the respective data type as low [bottom 15%], intermediate and high [top 15%]) could potentially act as
biomarkers and therapeutic targets.
doi:10.1371/journal.pone.0024709.g008
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50,000 molecular features to fewer than 200, which are most
associated with tumor recurrence and patient survival. The
integrated PFS signature provided better prediction than signa-
tures based on individual data types. The predictive performance
of the integrated PFS signature was independent of the method of
stratification into discrete risk categories.
Our results demonstrate that signatures based on multiple data
types can be more powerfully predictive than those based on a single
data type and this may be true for other tumor types as well. For
serous ovarian cancer, we provide a new prediction tool for patient-
specifictimetorecurrenceandsurvivalthatcanbeusedbyphysicians
to predict likely disease progression following surgery and molecular
profiling. In addition, the gene signatures identified and pathways
differentially affected in patients more resistant to standard therapy,
may prove useful for the discovery of therapeutic targets in the
contextof efforts to improve therapy for high-grade SeOvCa patients.
In particular, our feature ranking method identified RNF10, ID4,
SLAMF7, HOXA4, ALOX12 and CAMKK2 (among others) as the
potentially most interesting biomarkers and therapeutic targets.
Materials and Methods
Traditionally, a univariate Cox proportional hazards regression
model is used to relate expression to outcome. In this method,
significant genes are selected based on arbitrary p-value cut-offs
and thresholding of the associated Wald z-statistic. A training
cohort is used to compute risk scores followed by strata creation
based on thresholding of these scores. The limitations of this
approach include not just the arbitrariness of the imposed
stratification, but also the arbitrarily chosen p-value cut-offs.
An alternative approach is to use penalized proportional hazards
(PH) regression, including the L1 (Lasso) and L2 penalized
estimation (Ridge regression). Including all genes in the predictive
model introduces noise and can lead to a poor predictive model.
The L1-based PH regression performs feature selection and
shrinkage simultaneously, and appears to outperform the univariate
Cox approach [35,36]. Here, we implemented an L1-regularized
Cox proportional hazards model to do feature selection using the
Coxmodelwith anL1 penalty,asproposedbyParkand Hastie[11].
Given the availability of clinical times, in addition to predicting
discrete patient risk stratification, we implemented an algorithm to
directly compute the continuous variables, the clinical times-to-event
(PFS and OS) based on an algorithm discussed in Heller and
Simonoff [37]. In an earlier study [38], an accelerated failure time
model was used to predict median survival times for patients with
progressive metastatic disease using clinicopathological factors.
The estimated concordance index for the validation data was
reported to be 0.67, with substantial variability in the actual
survival among patients with similar predicted median times. In
another study [39], a nomogram based on a Cox model was
constructed for finding patient-specific probabilities of metastasis-
free survival in patients with recurrent prostrate cancer following
surgery and/or radiation therapy resulting in prostate-specific
antigen level as a prognostic marker. A bootstrap concordance
index was computed to assess the performance of the prognostic
marker and was reported to be 0.69.
All data in TCGA including the data used in this study [1] have
the appropriate IRB consent. Details of the methods used in this
study are as follows:
Multivariate Cox Regression model
The CoxPath model [11] is a path following algorithm for the
L1-regularized Cox proportional hazards model. Here, the
coefficients (b) for the predictors (x9) are estimated by solving a





The partial likelihood function (L) with respect to the given data
{(xi,y i):i=1, …., n} is:
















where Ri is the risk set at time yi and di is a binary variable for
censored data. Analogous to Lasso [40], which adds a complexity
penalty term to the squared error loss criterion, the CoxPath is
modified with regularization as:
^ b b(l)~argmin
b
{log Ly ;b ðÞ fg zlb kk 1
  
where l.0 is the regularization parameter.
A predictor-corrector algorithm is used to determine the entire
path of the coefficient estimates as l varies, i.e., find b(l) starting
from l=lmax to l=0; where lmax is the largest l that makes b(l)
non-zero. The algorithm computes a series of solution sets, each
time estimating the coefficients with a smaller l based on the
previous estimate. The solution paths are calculated that satisfy
^ b bl 1 ðÞ ~argmin
b







where l1 e (0, ‘). l2 is a fixed, small, positive constant as referred
to in the original Park and Hastie reference [11] which removes
degeneracy and instability due to strong correlations between
covariates. When the correlations are not strong, the effect of the
quadratic penalty with a small l2 is negligible.
We employ the concordance probability estimate (CPE) for
parameter tuning in the CoxPath model. Two-fold cross-
validation, repeated 10 times, is performed to obtain concordance
probability estimates (CPE) at different values of the regularization
parameter. The optimal parameter is chosen that maximizes the
CPE in the cross-validation procedure.
The concordance probability estimate (CPE)
The predictive strength of the CoxPath algorithm was assessed
using the concordance probability estimate (CPE). Go ¨nen and
Heller [41] derived an analytic expression for the concordance
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where xij represents the pairwise difference xi - xj; h is a scaling
parameter that is used to smooth the CPE and W is a local
distribution function. The concordance probability is used to
evaluate the discriminatory power and the predictive accuracy of
the Cox proportional hazards model. A concordance probability
of 1.0 represents a model that has perfect discrimination, and a
value of 0.5 indicates a random prediction. A strong concordance
signifies that the baseline factors in the Cox model are highly
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between any two patients at time t.
We used two methods for evaluating the predictive performance
of the derived prognostic signatures. One approach predicts the
patient-risk stratification utilizing the features estimated by Lasso-
Cox approach (along with the calculation of hazard ratios and p-
values). A second approach predicts the clinical time-to-event using
an algorithm discussed by Heller and Simonoff [37].
The Prognostic Scores
c-score. A prognostic index based on the linear predictor





where xi is the value of each gene (or microRNA) in the signature and
bi is the estimated regression coefficient of that gene obtained from the
CoxPath model. Patients were stratified into three groups (low-,
intermediate-a n dhigh-risk groups) using tertile stratification based on the
training data. The c-scores and the cut-offs derived from the training
cohort were applied directly to test cohorts and were not re-estimated.
t-score. The prognostic index based on t-score was calculated
as the difference in the average of the poor prognosis genes with
the average of the good prognosis genes for each tumor profile
based on the genes obtained from the CoxPath model [11].
Time to Recurrence Prediction
Fitting a regularized multivariate regression model using Lasso-
Cox allows us to compute the predicted median time-to-event. For
this purpose, we utilized the median failure time model developed
by Heller and coworkers [37]. The median time-to-event for a given
X is where
^ S S0(t)~ ^ S S(t,X)~:5
   exp({x0^ b b)
For a given covariate profile, the predicted median time refers to the
time point that one would predict 50% of the cohort to survive beyond.
Data Integration
Genomic data integration, the process of statistically combining
diverse sources of information from multiple data types to make
large-scale predictions, is becoming increasingly prevalent. In
performing integration, it is advisable to assess the degree to which
predictive power increases with the addition of more features and
to investigate the biological interpretation of the resulting features.
Various integration methods are available that include kernel
space integration [42] for machine learning analysis, sparse
canonical correlation analysis [43], and iCluster [44]. We are
interested in a method that works with as few features as possible,
is amenable to biological interpretation of the resulting discrim-
inant features and optimizes association with outcome measures.
There are various mechanisms that regulate gene expression.
These include DNA methylation, histone modification, DNA
copy-number gain/loss, and targeting by transcription factors and
microRNAs. Using features derived from integration of various
data types may lead to richer biologically relevant information
than the analysis of a single data type.
In summary, to overcome possible limitations of other
integration methods, we have created an integration method that
reduces the dimensionality of the feature space with the intent that
the resulting features are biologically significant. The vector space
integration used here (Figure 2 and Supplementary File S5) is
similar to integration approaches in support vector machine
analysis [45]. We began by computing Spearman rank correlations
among different data types: mRNA and copy-number; mRNA and
DNA methylation; and mRNA and microRNA, respectively, as
these data types are not completely independent of each other.
Next we used three separate cut-offs respectively for each
potentially correlated data pair to filter the features for input into
Cox Lasso cross-validation analysis. Our aim was to identify
potential targets for therapy in the context of multiple genomic
characteristics and to provide more accurate prognostic and
predictive assessment than is possible without data integration.
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